News & Insights

Compared to what? How the choice of comparator affects new medicines

Comparator choice shapes health technology assessment: it sets the benchmark a new medicine is assessed against, driving both patient access and where firms invest in R&D. We consider five theoretical comparator examples and, for each, assess the implications of comparator selection on access, launch decisions and innovation incentives for new medicines.

Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem

America’s dependence on foreign generic manufacturing is a real national security and supply concern. The vast majority of drug shortages in the U.S. are generics and shortages have increasingly burdened pharmacies across the country and disrupted care for the patients who rely on them, particularly those with chronic pain and cancer.

But President Trump’s most recent policy is unlikely to fix that problem. It’s far more likely to make American medicine cabinets less reliable, not more.

What the first EU JCA reveals about assessing precision oncology 

We explore how the first JCA provides insights into the longstanding methodological challenge of evidence generation and comparative assessment for precision medicine.

What is a life worth in climate policy? It depends on who you ask 

The ECOnomic Evaluation for Climate Action (ECO-CHICA) consensus guidance is now on SSRN, with the scoping review and methodological deep dives available alongside it. Here is what they say, and why the question in the title is harder than it looks.